To access this material please log in or register

Register Authorize

On the priority of antihyperglycemic therapy in type 2 diabetes mellitus: cardiovascular aspects of hypoglycemia

Ruyatkina L. A., Ruyatkin D. S., Berezovskaya G. A.

Keywords: hypoglycemia, treatment, diabetes mellitus, cardiovascular pathology

DOI: 10.18087/rhj.2013.4.1822

The review is focused on differential selection of antihyperglycemic agents for reduction of cardiovascular risk in patients with type 2 DM.
  1. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339 (4):229–234.
  2. Fonseca V. “Defining and characterizing the progression of type 2 diabetes”. Diabetes Care. 2009;32 (Suppl 2):S151–156.
  3. Wannamethee S, Shaper A, Whincup P et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171 (5):404–410.
  4. Graham I, D,Agostino R. Managing Cardiovascular Risk. – Atlas Clinical Publishing Ltd. 2007. –112 p.
  5. Baily C. Metformin. The Gold Standard. – Wiley & Sons, Incorporated, 2008. –247 p.
  6. Terry T, Raravikar K, Chokrungvaranon N et al. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14 (1):79–88.
  7. Викулова О. К. Профилактика риска сосудистых осложнений – новые показания к терапии Диабетоном МВ. Сахарный диабет. 2012;3:84–88.
  8. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35 (6):1364–1379.
  9. Finfer S. Hypoglycemia in critically ill adults – association yes, causation not proven. Crit Care. 2011;15 (6):1012.
  10. Desouza C, Bolli G, Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care. 2010;33 (6):1389–1394.
  11. Zammitt N, Frier B. Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28 (12): 2948–2961.
  12. Matyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997;20 (2):135–141.
  13. Adler G, Bonyhay I, Failing H et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigo­rous glycemic control. Diabetes. 2009;58 (3):360–366.
  14. Kitsios K, Tsapas A, Karagianni P. Glycemia and cardiovascular risk: challenging evidence based medicine. Hippokratia. 201;15 (3):199–204.
  15. Rana O, Byrne C, Kerr D et al. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation. 2011;124 (14):1548–1556.
  16. Лаптев Д. Н., Шмушкович И. А. Аритмогенный эффект гипогликемии. Сахарный диабет. 2012;1: 25–30.
  17. Robinson R, Harris N, Ireland R et al. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with Type 1 diabetes. Diabetologia. 2004;47 (2):312–315.
  18. Marques J, George E, Peacey S et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997;14 (8):648–654.
  19. Heller S. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl. 2002; (129):27–32.
  20. Veglio M, Chinaglia A, Cavallo Perin P. The clinical utility of QT interval assessment in diabetes. Diabetes Nutr Metab. 2000;13 (6):356–365.
  21. Pop-Busui R. Cardiac Autonomic Neuropathy in Diabetes. A clinical perspective. Diabetes Care. 2010; 33 (2): 434–441.
  22. Koivikko M, Salmela P, Airaksinen K et al. Effects of sustained insulin-induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes. 2005;54 (3):744–750.
  23. Trovati M, Anfossi G, Cavalot F et al. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986;35 (7):818–825.
  24. Grant P, Stickland M, Wiles P et al. Hormonal control of haemostasis during hypoglycaemia in diabetes mellitus. Thromb Haemost. 1987;57 (3):341–344.
  25. Oishi K, Uchida D, Ohkura N et al. Ketogenic diet disrupts the circadian clock and increases hypofibrinolytic risk by inducing expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2009;29 (10):1571–1577.
  26. Wright R, Newby D, Stirling D et al. Effects of Acute Insulin-Induced Hypoglycemia on Indices of Inflammation. Diabetes Care. 2010;33 (7):1591–1597.
  27. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun. 1988;157 (3):1190–1196.
  28. Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. Eur Heart J. 2012;14:4–13.
  29. Miller ME, Bonds DE, Gerstein HC et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340: b5444.
  30. Donnelly L, Morris A, Frier B et al. The DARTS / MEMO Collaboration: Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population based study. Diabet Med. 2005;22 (6):749–755.
  31. Herings R, de Boer A, Stricker B et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345 (8959):1195–1198.
  32. Grégoire F, Pariente A, Fourrier-Reglat A et al. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. Br J Clin Pharmacol. 2008;66 (1):142–145.
  33. Kirkman M, Briscoe V, Clark N et al. Diabetes in Older Adults. Diabetes Care. 2012;35 (12):2650–2664.
  34. Skyler J, Bergenstal R, Bonow R et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32 (1):187–192.
  35. Deacon C, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metabol. 2012;14 (8):762–767.
  36. Banarer S, McGregor V, Cryer P. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes. 2002;51 (4):958–965.
  37. Canadian Agency for Drugs and Technologies in Health (CADTH). Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes. CADTH Technol Overv. 2010;1 (1):e0113.
  38. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367 (4):319–328.
  39. Бирюкова Е. В., Аметов А. С., Анциферов М. Б. с соавт. Метаболические и сердечно-сосудистые эффекты раннего назначения инсулина гларгин: по результатам исследования ORIGIN. Сахарный диабет. 2012;3:92–100.
  40. Knop F, Vilsbøll T, Larsen S et al. No reactive hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care. 2003;26 (9):2581–2587.
  41. Fakhoury W, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86 (1):44–57.
  42. Seck T, Nauck M, Sheng D et al. Sitagliptin Study 024 Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‑year study. Int J Clin Pract. 2010;64 (5):562–576.
  43. Arechavaleta R, Seck T, Chen Y et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism. 2011;13 (2):160–168.
  44. Hollander P, Raslova K, Skjøth T et al. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011;13 (3):268–275.
  45. Abbatecola A, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25 (11):913–925.
  46. Nauck M, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4‑inhibitor, sitagliptin, compared with sulfonylurea, glipizide in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, dooble-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9 (2):194–205.
  47. Monami M, Dicembrini I, Martelli D et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 (3):57–64.
Ruyatkina L. A., Ruyatkin D. S., Berezovskaya G. A. On the priority of antihyperglycemic therapy in type 2 diabetes mellitus: cardiovascular aspects of hypoglycemia. Russian Heart Journal. 2013;12(4):207-213

To access this material please log in or register

Register Authorize
Ru En